February 28, 2007 (San Diego) — Combined therapy with the inhaled corticosteroid budesonide and the long-acting beta-agonist formoterol ( Symbicort) produces bronchodilation as rapidly as does ...

PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc (VTRS). (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced approval of the first generic of Symbicort — budesonide and formoterol fumarate dihydrate — ...

Wilmington, DE – February 24, 2007 – New data demonstrated the maintenance combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dehydrate ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed the hybrid medicine budesonide/formoterol fumarate dihydrate (Teva Pharma B.V.) for the ...

Switching from a metered-dose to a dry-powder inhaler after a formulary change increased emergency department visits and hospitalizations in people with COPD or asthma. The absolute changes in risk ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β 2-agonist may be an alternative to conventional treatment strategies. We conducted a 52-week, double-blind ...

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...

In double-blind, placebo-controlled trials, budesonide–formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β 2-agonist ...

Hangzhou Changxi Pharmaceutical Co., Ltd. (Changxi Pharmaceutical), a clinical-stage biotechnology company, announced that it has entered into an exclusive commercialization collaboration in mainland ...